UPDATE 1-GSK diabetes drug set for European approval

Comments (1)
raroman wrote:

This week two long awaited new human clinical trial results in which the effect of Transmax Resveratrol as a preventative and adjunct treatment for Type 2 Diabetes were released.  What distinguishes these recent human trials is the larger number of subjects tested, the rigid selection criteria used, and the examination of Resveratrol’s effects on body weight, blood pressure, cholesterol, and overall health effects in addition to Resveratrol’s benefits to the obese and diabetic patients.  In these human clinical trials Transmax was shown to have important beneficial action with respect to both prevention of Metabolic Syndrome from evolving into Type 2 Diabetes. Specifically, transmax lowered blood glucose and blood pressure, improved insulin sensitivity, and caused a weight loss in obese patients. Evidence was also presented which confirms that Transmax Resveratrol could attenuate many of the pathologies associated with severe Diabetes, including loss of vision, circulatory problems, and chronic inflammation.

Jan 24, 2014 5:32pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.